Intended Use
This kit is for research use only. Under no circumstances should it be used for therapeutic or diagnostic applications.
Contents of Kit
1. PEG-BSA coated plate (12 × 8-wells). Store at 4°C
2. Anti-IgG HRP Stock. Store at 4°C
3. Anti-PEG Stock. Store at 4°C
4. 20× HRP PEG Wash, 50 ml
5. HRP PEG Diluent, 50 ml
6. TMB, 12 ml
7. Stop Solution, 7 ml
Storage
All components should be stored at 4°C. The microtiter plate should be kept in a sealed bag with desiccant. Kits will remain stable for 12 months from the date of purchase provided that the components are stored as described.
General Description
Attachment of polyethylene glycol (PEG) chains to therapeutic biologic agents, a process referred to as PEGylation, prolongs the circulating half-life of the modified protein by slowing proteolytic degradation and by masking it from the immune system. However, it has been reported that repeated injections of PEGylated proteins can induce anti-PEG antibodies that increase the rate of clearance and decrease drug efficacy (accelerated blood clearance, or ABC phenomenon). To aid research in this important area, we have developed a Mouse anti-PEG IgG ELISA kit.
Standard Curve
A typical standard curve is shown below. This curve is for the purpose of illustration only. A standard curve must be run with each experiment.
Citations
Have you cited DEIA6159 in a publication?
Let us know and earn a reward for your research.
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
| Product Name |
Cat. No. |
Applications |
Host Species |
Datasheet |
Price |
Add to Basket |
Tong, WH; Pieters, R; et al. A prospective study on drug monitoring of PEGasparaginase and Erwinia asparaginase and asparaginase antibodies in pediatric acute lymphoblastic leukemia. BLOOD 123:2026-2033(2014).
August, KJ; Miller, WP; et al. Comparison of Hypersensitivity Reactions to PEG-Asparaginase in Children After Intravenous and Intramuscular Administration. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY 35:E283-E286(2013).